Asian Myeloproliferative Neoplasm (MPN) Registry

Last updated: May 21, 2023
Sponsor: The University of Hong Kong
Overall Status: Active - Recruiting

Phase

N/A

Condition

Leukemia (Pediatric)

Leukemia

Post-essential Thrombocythemia Myelofibrosis

Treatment

N/A

Clinical Study ID

NCT05882773
AMWG002
  • Ages > 18
  • All Genders

Study Summary

This is a multinational, multicenter, prospective and retrospective, observational, cohort study of patients with myeloproliferative neoplasm.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age ≥ 18 years old at the time of diagnosis of MPN.
  2. Subject was diagnosed with one of the following disorders according to the 2017 WHOclassification (for patients diagnosed before 2017, the bone marrow reports will bere-evaluated according to the 2017 WHO classification):
  3. Polycythaemia vera
  4. Essential thrombocythemia
  5. Primary myelofibrosis, pre-fibrotic/early stage
  6. Primary myelofibrosis, overt fibrotic stage
  7. Post-polycythaemia vera myelofibrosis
  8. Post-essential thrombocythaemia myelofibrosis
  9. MPN-unclassifiable
  10. All subjects need to provide informed consent.

Exclusion

Exclusion Criteria: A subject will not be eligible if he/she meets any of the following criteria:

  1. Subject was diagnosed with myelodysplastic syndrome, myelodysplasticsyndrome/myeloproliferative neoplasm, or chronic myeloid leukaemia BCR-ABL1 positive, underthe 2017 WHO classification

Study Design

Total Participants: 1000
Study Start date:
May 01, 2023
Estimated Completion Date:
December 31, 2026

Study Description

This is a multinational, multicenter, prospective and retrospective, observational, cohort registry of patients with MPN. The registry mainly involves study centres in Asia including but not limited to Hong Kong, Singapore, Malaysia, Taiwan, Korea and Thailand. Clinicopathologic characteristics, cytogenetic characteristics, mutational characteristics, treatment characteristics, outcomes and survivals of Asian patients MPN diagnosed between 2010-2025 will be collected to establish clinical registry.

Data on the clinicopathologic characteristics, cytogenetics, mutational profile, prognostic scoring treatment characteristics, responses to treatment, outcome and survivals will be collected through routine clinic visits and/or reviewing medical records. Data will be collected at diagnosis, and approximately every 6 months thereafter (for prospective data) and at progression until death/study termination.

Connect with a study center

  • Department of Medicine, Queen Mary Hospital

    Hong Kong,
    Hong Kong

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.